Last reviewed · How we verify

NCT05617417

The Efficacy of Injectable Platelet-rich Fibrin in the Treatment of the Female Stress Urinary Incontinence

Completed NA Last updated 15 November 2022
What this trial tests

NA trial testing Local applied injectable platelet-rich fibrin in women with stress urinary incontinence in Urinary Incontinence in 30 participants. Completed in 5 September 2021.

Timeline
5 May 2021
Primary endpoint
26 August 2021
5 September 2021

Quick facts

Lead sponsorAbant Izzet Baysal University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date5 May 2021
Primary completion26 August 2021
Estimated completion5 September 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Abant Izzet Baysal University

Who can join

Adults 25 to 75, female only, with Urinary Incontinence or Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We aimed to evaluate the efficacy of locally applied injectable platelet-rich fibrin in women with stress urinary incontinence. We searched whether there was a decrease in the severity of urinary incontinence after the injection of platelet-rich fibrin. The participants will answer questionnaires about urinary incontinence before and after the injectable platelet-rich fibrin treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Urinary Incontinence

Currently open trials in the same condition.

Other Abant Izzet Baysal University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing